




## Major Advance for Second Generation AirSonea® Wheeze Monitor

**Melbourne, Australia and Haifa, Israel - 6 August 2015**

Medical technology company iSonea Limited (ASX:ISN) announces a major advance for its Second Generation AirSonea® Wheeze Monitor with new software solutions for breath sound screening.



Extensive user testing revealed that incorrect positioning of the first Generation AirSonea sensor could result in recordings without breath sounds and therefore no capacity to detect continuous adventitious breath sounds (CABS).

The Second Generation AirSonea wheeze detection algorithm includes a breath-screening module to ensure the device will only record and pass sounds through to wheeze analysis when breath is detected. The app warns when breath is not detected and allows the user to reposition the sensor correctly without the need to stop the recording and start again.

**ENDS**

Contact:  
Leon L'Huillier  
Chairman  
+61 (0)3 9653 9321

## Forward Looking Statements

Certain statements made in this presentation are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this presentation. The forward looking statements made in this presentation relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

### Forward Looking Statements & Medical Device Risks/General Medical Device Risks

- Medical device R&D involves medical and scientific uncertainty and long lead times and there is no certainty that any particular event will occur within a certain time period.
- Technology changes in the medical device and digital health industry are accelerating and new technologies emerge.
- Market acceptance of medical devices is uncertain and can be impacted by difficulties in marketing, acceptance by patients and clinicians, delays in marketing and the advancement of new competitive products.
- Medical device R&D and manufacturing activities require funding over a long period of time and more working capital is often required to complete development and commercialisation of certain products.
- Government health regulations, which are subject to change, add uncertainty to obtaining approval to market medical devices.
- Obtaining, securing and maintaining rights to technology and patents are an integral part of securing potential product value and can lead to patent disputes.
- The loss of key personnel can have an adverse impact.
- Potential product liability risks and warranty claims are inherent in the manufacturing, marketing and use of human medical devices.